Sagimet Biosciences Inc. (SGMT) short interest & options flow
NASDAQSagimet Biosciences enters October with a sharply divided analyst register and a short position that has been growing steadily all month, while the stock itself has shed nearly 16% in a week. The most consequential development this week was Goldman Sachs reinstating coverage on September 24 with a Sell rating and a $7 price target, a call that lands well below the current price of…
SGMT Barclays analyst upgrades to Overweight, raises target to $18 from $8, implying 68% upside from current $10.71.
- Market cap
- $698M
- Next earnings
- 13 Nov 2026
Key data as of 7 Nov 2026
Latest signals on SGMT
- Analyst
SGMT Barclays analyst upgrades to Overweight, raises target to $18 from $8, implying 68% upside from current $10.71.
- Short Interest
SGMT short interest surges 26.7% in one week to 14.46% of float, with massive share availability at 1,696% offsetting minimal borrowing costs of 0.47%.
- Cost to Borrow
SGMT cost to borrow surges to 0.78% — up 345% in one week as shares become harder to locate.
SGMT news and analysis
RSSNo long-form analysis yet for SGMT. Pulse alerts and the live data picture are available on ORTEX.
Open SGMT on ORTEX →Want the live picture for SGMT?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SGMT — free to start on ORTEX.
Sign up for free →Open SGMT on ORTEX